Effect of Glycine on Lead Mobilization, Lead-Induced Oxidative Stress, and Hepatic Toxicity in Rats by Alcaraz Contreras, Yolanda et al.
Hindawi Publishing Corporation
Journal of Toxicology
Volume 2011, Article ID 430539, 7 pages
doi:10.1155/2011/430539
Research Article
Effect of Glycine on LeadMobilization, Lead-Induced Oxidative
Stress, and Hepatic Toxicity in Rats
Yolanda Alcaraz-Contreras,1, 2 Lourdes Garza-Ocan˜as,2 Katya Carcan˜o-Dı´az,3
and Xo´chitl Sofı´a Ramı´rez-Go´mez2, 4
1Divisio´n de Ciencias Naturales y Exactas, Departamento de Farmacia, Universidad de Guanajuato,
Noria Alta s/n, 36050 Guanajuato, Gto., Mexico
2Departamento de Farmacolog´ıa y Toxicolog´ıa, Facultad de Medicina, Universidad Auto´noma de Nuevo Leo´n,
Gonzalitos 235 Norte, Col Mitras Centro, 64460 Monterrey Nuevo Leo´n, Mexico
3Departamento de Histolog´ıa, Facultad de Medicina, Universidad Auto´noma de Nuevo Leo´n, Monterrey Nuevo Leo´n, Mexico
4Divisio´n de Ciencias de la Salud, Departamento de Medicina y Nutricio´n,
Universidad de Guanajuato, 20 de Enero 929, 37320 Leo´n, Gto., Mexico
Correspondence should be addressed to Lourdes Garza-Ocan˜as, logarza@live.com.mx
Received 8 March 2011; Accepted 26 May 2011
Academic Editor: Jack Ng
Copyright © 2011 Yolanda Alcaraz-Contreras et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The eﬀectiveness of glycine in treating experimental lead intoxication was examined in rats. Male Wistar rats were exposed to
3 g/L lead acetate in drinking water for 5 weeks and treated thereafter with glycine (100 and 500mg/kg, orally) once daily for
5 days or glycine (1000mg/kg, orally) once daily for 28 days. The eﬀect of these treatments on parameters indicative of oxidative
stress (glutathione and malondialdehyde levels), the activity of blood δ-aminolevulinic acid dehydratase, and lead concentration
in blood, liver, kidney, brain, and bone were investigated. Liver samples were observed for histopathological changes. Glycine was
found to be eﬀective in (1) increasing glutathione levels; (2) reducing malondialdehyde levels; (3) decreasing lead levels in bone
with the highest dose. However, glycine had no eﬀect on lead mobilization when 100 and 500mg/kg glycine were administered. In
microscopic examination, glycine showed a protective eﬀect against lead intoxication.
1. Introduction
Lead is a pollutant with no beneficial biological role, and its
toxicity causes numerous malfunctions. The liver, kidneys,
and brain are considered to be the target organs for the toxic
eﬀects [1]. Although human lead toxicity has decreased since
discontinuation of the use of lead as a gasoline additive, its
exposure continues to be a public health problem across
the world [2]. A number of recent studies confirmed the
possible involvement of reactive oxygen species in lead-
induced toxicity [3, 4]. Oxidative stress has been implicated
for its contribution to lead-associated tissue injury in the
liver, kidneys, brain, and other organs. In this context,
several studies have been conducted to determine the eﬀect
of antioxidant supplementation in lead intoxication [5–8].
Ascorbic acid, vitamin E, methionine, and α-lipoic acid have
been administered along with lead or after lead exposure.
Data suggest that antioxidants may play an important role in
abating some hazards of lead, increasing lead mobilization,
and providing recoveries in altered biochemical variables
[9, 10].
Recently, glycine, the simplest of the amino acids, has
been given a lot of importance for its antioxidant eﬀects [11].
Shaikh and Tang [12] investigated the eﬀect of glycine on
chronic cadmium toxicity in rats and reported that glycine
protects against cadmium-induced hepatotoxicity as well as
nephrotoxicity by blocking the lipid peroxidation. Deters
et al. [13] reported that glycine prevented damage induced
in isolated perfused rat livers by some hepatotoxic agents.
This protection was evaluated by the reduction of lipid
peroxidation (LPO) and the increase of glutathione (GSH)
levels.
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Al-Neamy et al. [14] determined the eﬀect of blood lead
on the plasma levels of amino acids in exposed lead workers.
They reported that nonessential amino acids such as glycine
showed significantly higher values in exposed workers than
in nonexposed workers. On the other hand, Sanguinetti
et al. [15] reported an abnormal excretion of glycine in
occupational exposure to lead workers. More recently, Okoko
and Awhin [16] reported that glycine can reduce cadmium-
induced alterations in culture cells. These findings support
the important antioxidant role of this amino acid.
Given the reported beneficial eﬀects of glycine in provid-
ing recovery in oxidative stress, it was considered worthwhile
to determine whether therapeutic benefits could be provided
if this amino acid was administered after lead exposure.
There is currently no basis for recommending the use of
antioxidants; in particular, their optimal doses for treating
lead intoxication are not yet known.
In this paper, we evaluated the eﬀect of glycine admin-
istration using three diﬀerent doses. We also evaluated the
eﬀect of duration of treatment with the highest dose. This
was done to determine the possible influence of the dose
of glycine on lead mobilization and its protection in lead-
induced oxidative stress and to make a correlation between
these parameters and histopathological liver changes.
2. Materials andMethods
2.1. Animals. All experiments were performed using adult
male Wistar rats, weighing 160 ± 20 g, housed in stainless
steel cages in a temperature controlled (22◦C) room main-
taining a 12 h light:dark cycle. The rats were allowed standard
rat chow and water ad libitum throughout the experiment.
Thirty animals were randomized into six groups (n = 5).
Group I, the negative control, was given only standard rat
chow and water. Group II, the positive control, received
3 g/L lead acetate in their drinking water ad libitum for 5
weeks; for 5 days afterwards, this group received plain water.
Group III received 3 g/L lead acetate in their drinking water
during weeks 1–5, and glycine (100mg/kg) was given for 5
days afterwards. Group IV received 3 g/L lead acetate in their
drinking water during weeks 1–5, and glycine (500mg/kg)
was given for 5 days afterwards. Group V received 3 g/L
lead acetate in their drinking water during weeks 1–5,
and glycine (1000mg/kg) was given for 28 days afterwards.
Group VI, exposed to lead for 5 weeks, was the positive
control; rats in this group received plain water for 28 days
afterwards.
The glycine solutions were freshly prepared and were
administered by gavage (stomach tube) at three doses (100,
500, and 1000mg/kg body weight). Control animals were
administered water in the same way on the same schedule.
One day after the last treatment, rats were anesthetized with
sodium pentobarbital and blood samples were collected with
lead-free needles via intracardiac puncture. The right femur
and organs (liver, both kidneys, and brain) were resected and
rinsed in cold saline, weighed, and used for lead analysis and
biochemical assays. Rat livers were washed in situ via the
portal vein with cold saline.
2.2. Blood δ-Aminolevulinic Acid Dehydratase. The activity
of blood δ-aminolevulinic acid dehydratase (ALAD) was
assayed according to the procedure of Tomokuni [17].
Briefly, 0.2mL of heparinized blood was mixed with 1.3mL
of distilled water and incubated for 10min at 37◦C for
complete hemolysis. After adding 1mL of standard δ-
aminolevulinic acid, the tubes were incubated for 60min at
37◦C. The reaction was stopped after 1 h by adding 1mL
of trichloroacetic acid (TCA). An equal volume of Ehrlich
reagent was added to the supernatant, and absorbance at
555 nm was recorded after 5min.
2.3. Hepatic and Renal GSH. To determine hepatic and renal
GSH concentration, 0.25 g of tissue sample was homogenized
on ice with 0.75mL of phosphate buﬀer. A 5% TCA
supernatant of the homogenate was poured into the mixture
with the 5,5
′
-bis-dithionitrobenzoic acid (Ellman reagent),
and the absorbance at 412 nm was measured [18]. The
GSH concentration in the samples was determined using a
calibration curve obtained from a GSH standard solution.
2.4. Hepatic and Renal LPO. Lipid peroxidation, as estimated
by the formation of malondialdehyde (MDA), was deter-
mined for hepatic and renal samples using the technique of
Ohkawa et al. [19]. Briefly, the tissue samples were minced
and homogenized in a ratio of 1 g of wet tissue to 4mL of
phosphate buﬀer (pH = 7.4). Homogenates (0.1mL) were
added into 0.2mL of 8.1% sodium dodecyl sulfate, 1.5mL
of 20% acetic acid, 1.5mL of 0.8% thiobarbituric acid (TBA),
and 0.7mL of distilled water. Samples were heated for 60min
at 95◦C. After cooling with tap water, a mixture of n-butanol
and pyridine (15 : 1, v/v) was added, and the mixture was
shaken vigorously. Following centrifugation at 4000 rpm for
10min, the absorbance of the organic layer was measured at
532 nm. The concentration of the TBA–MDA complex in the
samples was determined using a calibration curve obtained
from a 1,1,3,3,-tetraethoxypropane standard solution.
2.5. Blood and Tissue Lead Determination. For blood, liver,
kidney, brain, and bone, wet tissue weight and volume of
blood were recorded. After tissue digestion with concen-
trated HNO3 using a Microwave Digestion System (Model
MDS 2000), samples were brought to a constant volume and
tissue lead content was determined following the procedure
standardized in our laboratory according to the NOM-199-
SSA1-2000 [20] using an atomic absorption spectropho-
tometer (PerkinElmer Zeeman 5100).
2.6. Protein Determination. The Lowry method [21] was
used to determine the protein content of the tissue homo-
genates.
2.7. Histopathological Changes. The liver was removed,
rinsed with normal saline, and cut into small pieces. Tissue
pieces were fixed in solutions and paraﬃn embedded.
Specimens were cut into 5 μm thick sections and stained
with hematoxylin and eosin (H&E stain), and apoptosis mea-
sured by DNA fragmentation was quantified using TUNEL
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Figure 1: Therapeutic eﬃcacy of glycine (100mg/kg) on GSH levels in the liver and kidney of lead-exposed rats. Values are mean ± SE;
n = 5. ∗P < 0.05 compared with positive lead control.
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Figure 2: Therapeutic eﬃcacy of glycine (100mg/kg) on LPO levels in liver and kidney of lead-exposed rats. Values are mean ± SE; n = 5.
∗P < 0.05 compared with positive lead control.
assays. We used histological sections and a commercial kit
(Trevigen). Histopathological changes were observed by light
microscopy. The following parameters were evaluated: (1)
liver architecture, (2) cell characteristics, and (3) nuclei char-
acteristics.
2.8. Statistical Analysis. Data comparisons were conducted
using a one-way analysis of variance followed by Tukey’s post
hoc test to compare results between the diﬀerent treatment
groups. A diﬀerence between animals exposed and not
exposed to lead (with or without glycine treatment) with
P < 0.05 was considered significant.
3. Results
Lead exposure caused a significant increase in its levels in
blood, brain, liver, kidney, and bone samples compared with
samples from controls (Table 1). Levels of lead in the blood
and the soft tissues decreased significantly in the control
group that was exposed to lead for 5 weeks and then received
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Figure 3: Histological lesions in the liver of rats exposed to lead. (a) Structure of a classic lobule with severe damage (H&E stain ×20). (b)
Inflammatory cell infiltration (H&E stain ×64). (c) Irregular membrane cell, condensed and eosinophilic cytoplasm (H&E stain ×64). (d)
Hyperchromatic and pyknotic nuclei (H&E stain ×64). (e) Apoptotic parenchyma cells (TUNEL stain ×64).
water for 28 days (Table 1). However, the levels did not
decrease to the values observed in rats not exposed to lead
(Table 1).
The data demonstrate that none of the treatments was
eﬀective inmobilizing lead from blood and soft tissues except
for the higher dose of glycine, which mobilized lead from the
femur (Table 2).
Lead intoxication caused a 70% inhibition of ALAD
activity. None of the glycine treatments returned the ALAD
activity to normal values.
Lead exposure caused a decrease in levels of hepatic and
renal GSH. These levels were increased with all treatments
and did not show a diﬀerence between treatments in rats not
exposed to lead. Figure 1 shows GSH levels in rats treated
with the lower dose of glycine.
Lead exposure caused an increase in the levels of hepatic
and renal lipid peroxidation. These levels were decreased
with all treatments and did not show a diﬀerence between
treatments in rats not exposed to Pb. Figure 2 shows LPO
levels in rats treated with the lower dose of glycine.
Histopathological examinations indicate that lead expo-
sure aﬀected the structural integrity of the liver, characterized
by extensive hepatocellular degeneration or necrosis, or
inflammatory cell infiltration. Congestion and dilatation of
sinusoidal and portal vein branches were also observed.
Hepatocytes were irregular in shape and showed changes in
nuclear and cell size with an increased nuclear/cytoplasmic
ratio with respect to the negative control group. The nuclei
were often hyperchromatic and pyknotic. Lead also induced
apoptotic fragments of DNA in liver observed through ter-
minal deoxynucleotidyl transferase-mediated dUTP labeling
(TUNEL) staining. Figure 3 shows liver tissue from rats
exposed to lead.
Treatment of lead-exposed animals with the lowest doses
of glycine showed marked improvement in histopathological
changes. Sinusoidal congestion in the liver was diminished,
and the portal vein diameter was normal. However, a high
proportion of apoptotic nuclei were seen in parenchyma
cells. Figure 4 shows liver sections from rats exposed to lead
and treated with glycine.
Treatment of lead-exposed animals with the higher doses
of glycine showed marked improvement in histopathological
changes. Sinusoidal congestion in the liver was diminished,
and portal vein diameter was normal. Apoptotic nuclei
were seen in parenchyma cells and around the central vein.
Figure 5 shows liver tissues from rats treated with glycine.
4. Discussion
One of the most notable observations in the present study
was the significant depletion of bone lead after glycine
(1000mg/kg) administration. However, glycine administra-
tion at daily doses of 100 and 500mg/kg for 5 days was
unable to induce an eﬀective decrease in this toxicokinetic
parameter of lead. This might be because a 5-day course of
treatment with glycine is inadequate to achieve optimum
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Figure 4: Histological lesions in the liver of rats exposed to lead and treated with glycine 100mg/kg for 5 days. (a) Classic liver lobule,
sinusoids, portal triads, and portal vein diameter were normal (H&E stain ×20). (b) Inflammatory cell infiltration (H&E stain ×64). (c)
Irregular membrane cell (H&E stain ×64). (d) Necrosis (H&E stain ×64). (e) Nucleus irregular in shape (H&E stain ×64). (f) Apoptosis
(TUNEL stain ×20).
Table 1: Lead concentration in the blood (μg/dL), brain, liver, kidney, and bone (μg/g) of rats. Lead was given in drinking water for 5 weeks,
after which, the lead was withdrawn and the rats (1) received plain water for 5 days or (2) received plain water for 28 days.
Control groups Blood Brain Liver Kidney Bone
Negative control 0.65 ± 0.23 0.21 ± 0.05 0.50 ± 0.17 0.20 ± 0.05 1.1 ± 0.3
Positive lead control1 39.2± 5.1a 1.54± 0.30a 2.3± 0.30a 10.9± 2.7a 514.5± 69a
Positive lead control2 24.3± 3.6a,b 0.90± 0.15a,b 1.0± 0.20a,b 6.7± 1.3a,b 407.4± 31.2a,b
aP < 0.05 compared with negative control values.
bP < 0.05 compared with positive lead control1.
eﬀects. We believe that duration of treatment as well as the
glycine concentration might be important.
Although one of the major drawbacks of lead mobiliza-
tion is its redistribution from bone to other critical tissues
[22, 23], we did not observe an increase in the levels of
lead in blood, liver, kidney, or brain tissues after glycine
treatment when they were compared with their respective
positive controls. This suggests that glycine can aﬀect lead
toxicokinetics in rats in a useful way.
The present study is the first reported that shows that
glycine is an amino acid eﬀective in mobilizing lead from
bone. The literature has indicated that sulfur compounds
such as methionine [24] increase the bioavailability of glu-
tathione, which is useful in chelating lead, thus counteracting
the toxic eﬀects of the metal. However, glycine is not a sulfur-
containing compound. It participates in GSH synthesis, and
it facilitates the γ-glutamyl cysteinyl ethyl ester-mediated
increase in intracellular GSH levels in rat hepatocytes [25].
Thus, GSH combines with certain nonnutrients, such as
drugs and poisons, and promotes their biotransformation
[26]. This might explain why lead bone levels are lowered as a
result of the combination of GSH with lead, with subsequent
excretion of the complex.
However, the mechanism by which glycine decreased
the level of lead in bone could not be explained explicitly
and requires further research, such as the measurement of
urinary and fecal lead excretion. Experiments along these
lines are already underway in our laboratory, and we are
continuing the evaluation of other antioxidants in rats using
diﬀerent doses.
The high concentration of lead in diﬀerent tissues
has been associated with oxidative stress, which might be
responsible, at least in part, for lead’s toxic eﬀects. We
observed that lead exposure results in a marked increase in
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Figure 5: Histological lesions in the liver of rats exposed to lead and treated with glycine 1000mg/kg for 28 days. (a) Classic liver lobule,
sinusoids, portal triads, and portal vein diameter were normal (H&E stain ×20). (b) Inflammatory cell infiltration (H&E stain ×64). (c)
Regular membrane cell, heterogeneous cytoplasm (H&E stain ×64). (d) Nucleus hyperchromatic with absence of basophilic staining (H&E
stain ×64). (e) Apoptotic cells in the parenchyma (TUNEL stain ×64). (f) Apoptotic cells around the central vein (TUNEL stain ×64).
Table 2: Lead concentration in the blood (μg/dL), brain, liver, kidney, and bone (μg/g) of rats. Lead was given in drinking water for 5
weeks, after which, the lead was withdrawn, and glycine (100 or 500mg/kg) treatment was given at a daily oral dose for 5 days, or glycine
(1000mg/kg) treatment was given at a daily oral dose for 28 days.
Treatments Blood Brain Liver Kidney Bone
Glycine (100mg/kg) 40.5 ± 2.3 1.25 ± 0.24 2.2 ± 0.20 10.1 ± 1.3 499.9 ± 16.3
Glycine (500mg/kg) 39.1 ± 2.1 1.41 ± 0.24 1.9 ± 0.30 9.1 ± 1.4 446.9 ± 42.8
Glycine (1000mg/kg) 22.5 ± 1.9 0.91 ± 0.18 0.80 ± 0.40 5.9 ± 1.7 306.9± 35.5a
aP < 0.05 compared with its positive lead control.
LPO in kidney and liver tissues. GSH levels were decreased
in rats exposed to lead. We found that glycine therapy was
eﬀective in mitigating all of the eﬀects of lead on parameters
indicative of oxidative stress. These findings were equally
observed at the three doses evaluated. On the other hand,
one of the most important physiological functions of GSH
is to protect the thiol groups located on some proteins and
enzymes such as ALAD from oxidizing [27]. Although the
three glycine treatments resulted in a significant increase
in GSH levels, we did not observe reactivity of ALAD. We
believe that the high levels of lead in blood in all groups
treated may also explain the lack of reactivity of ALAD.
In this regard, glycine has already been shown to have
protective eﬀects against lead intoxication. Its beneficial
eﬀects could be attributed to its ability to reverse measures
of oxidative stress, suggesting that glycine has an excellent
antioxidant eﬀect.
This study also showed that lead induced hepatotoxicity,
as evidenced by biochemical measurements and histopatho-
logical changes that were consistent with the observations
of other investigators [28]. It is of interest that despite the
glycine-induced reversal of measures of oxidative stress, the
histopathological examination of liver tissues confirmed that
there was still some cellular damage.
In conclusion, treatment with glycine significantly
decreased lead levels in bone and mitigated all of the
eﬀects of lead on parameters indicative of oxidative stress in
hepatic and renal samples. These findings show that glycine
has an important antioxidant activity and accelerates the
elimination of lead when it is administered at a high dose.
Journal of Toxicology 7
Treatment of rats with smaller and higher doses of glycine
provided similar protection against lead-induced cellular
liver damage and reversed completely the damage to classic
liver architecture.
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